



STUDI CLINICI: METODOLOGIA

Coordinatore Dr.ssa Stefania Gori

Evento ECM MODULO 4

REVISIONI SISTEMATICHE E METANALISI

NEGRAR 5/6 Aprile 2019 Centro Formazione IRCCS Ospedale Sacro Cuore Don Calabria

Definizione del quesito clinico e degli outcome di interesse

Defining the review question

A clearly defined, focused review begins with a well framed question.


The review question should specify:

- types of population (participants),
- types of interventions (and comparisons),
- types of outcomes that are of interest.

These components of the question, with the additional specification of types of study that will be included, form the basis of the pre-specified eligibility criteria for the review.

The 'clinical question' should specify the types of population (participants), types of interventions (and comparisons), and the types of outcomes that are of interest.

The acronym PICO (**P**articipants, **I**nterventions, **C**omparisons and **O**utcomes) helps to serve as a reminder of these.



Defining the review question

A statement of the review's objectives should begin with a precise statement of the primary objective, ideally in a single sentence.

Where possible the style should be of the form:

'To assess the effects of [*intervention or comparison*] for [*health problem*] in [*types of people, disease or problem and setting if specified*]'.

This might be followed by one or more secondary objectives, for example relating to different participant groups, different comparisons of interventions or different outcome measures.



				Review Manager 5	5.3						
) 🧉		<i>(</i> 2	🗈 🌒 😻 🖤 🏠	None	$\mathbf{e} \Diamond \mathbf{B} \mathbf{i} \mathbf{\underline{u}} \mathbf{x}^2 \mathbf{x}_2 \mathbf{y}$					
	O In the second se										
	New Review Wizard What is the title of the review?										
Ē	Title:		CVV:								
	Intervention] for [health problem]										
			101								
	0	[Intervention A]	versus	[intervention B]	for	[health problem]					
	\bigcirc	[Intervention]	for	[health problem]	in	[participant group/location]					
	[Use if title does not fit any of the formats above]										
l i	<u> </u>				_						
	Ca	incel		< Back Next :	>	Finish					

Defining the review question

A statement of the review's objectives should begin with a precise statement of the primary objective, ideally in a single sentence.

Where possible the style should be of the form:

'To assess the effects of [intervention or comparison] for [health problem] in [types of people, disease or problem and setting if specified]'.

This might be followed by one or more secondary objectives, for example relating to different participant groups, different comparisons of interventions or different outcome measures.

Defining the scope of a review question (broad versus narrow)

The questions addressed by a review may be broad or narrow in scope.

- A review might address a broad question regarding whether antiplatelet agents in general are effective in preventing all thrombotic events in humans.
- A review might address whether a particular antiplatelet agent, such as aspirin, is effective in decreasing the risks of a particular thrombotic event, stroke, in elderly persons with a previous history of stroke.

Screening for prostate cancer (Review)

Ilic D, Neuberger MM, Djulbegovic M, Dahm P Cochrane Database of Systematic Reviews 2013, Issue 1.

ΟΒЈΕСΤΙΥΕЅ

The primary objective of this review was to determine the efficacy of screening men for prostate cancer in reducing prostate cancerspecific and all-cause mortality.

The secondary objectives of this review were to:

- determine the impact of prostate cancer screening on quality of life and adverse effects; and
- document the costs of screening for prostate cancer.


Which Populations?

The criteria for considering types of people included in studies in a review should be sufficiently broad to encompass the likely diversity of studies, but sufficiently narrow to ensure that a meaningful answer can be obtained when studies are considered in aggregate.

It is often helpful to define the types of people that are of interest in two steps:

- ✓ diseases or conditions of interest using explicit criteria for establishing their presence or not;
- ✓ the broad population and setting of interest





Which Populations?

The criteria for considering types of people included in studies in a review should be sufficiently broad to encompass the likely diversity of studies, but sufficiently narrow to ensure that a meaningful answer can be obtained when studies are considered in aggregate.

It is often helpful to define the types of people that are of interest in two steps:

- ✓ diseases or conditions of interest using explicit criteria for establishing their presence or not;
- ✓ the broad population and setting of interest

Screening for prostate cancer (Review) Ilic D, Neuberger MM, Djulbegovic M, Dahm P

Cochrane Database of Systematic Reviews 2013, Issue 1.

Types of participants

All men enrolled in studies of prostate cancer screening were eligible for this review, with no exclusions based on ethnicity, age, or presence of lower urinary tract symptoms. Studies including men with a previous diagnosis and treatment of prostate cancer were excluded.

Which comparisons to make?

The second key component of a well-formulated question is to specify the interventions of interest and the interventions against which these will be compared (comparisons).

- Consider exactly what is delivered, at what intensity, how often it is delivered, who delivers it, etc.
- Are the interventions to be compared with an inactive control intervention (e.g. placebo, no treatment), or with an active control intervention (e.g. a different variant of the same intervention, a different drug, a different kind of therapy)?

Screening for prostate cancer (Review)

Ilic D, Neuberger MM, Djulbegovic M, Dahm P

Cochrane Database of Systematic Reviews 2013, Issue 1.

Types of interventions

Studies that used any of the following screening procedures, individually or in combination, were included:

- digital rectal examination (DRE);
- prostate-specific antigen (PSA) test (including total,

velocity, density, and percentage free and complex); and


• transrectal ultrasound (TRUS)-guided biopsy.

- **P.** Pazienti con mHSPC ad alto volume/rischio
- I. AAP/Doce + ADT
- C. ADT
- **O.** OS, PFS, QoL, Tollerabilità

Evidenze **direttamente trasferibili** nel caso la sola ADT rappresenti l'alternativa terapeutica *standard*

- P. Pazienti con mHSPC ad alto volume/rischio
- I. AAP/Doce + ADT
- C. ADT

O. OS, PFS, QoL, Tollerabilità





Important Questions

Should be from practice NOT evidence driven

- **P.** Pazienti con mHSPC ad alto volume/rischio
- I. AAP/Doce + ADT
- C. ADT
- O. OS, PFS, QoL, Tollerabilità

Evidenze direttamente trasferibili nel caso la sola ADT rappresenti l'alternativa terapeutica standard

- P. Pazienti con mHSPC ad alto volume/rischio
- I. AAP + ADT
- **C.** Doce + ADT
- O. OS, PFS, QoL, Tollerabilità




Evidenze disponibili **NON direttamente trasferibili** alle richieste del quesito P.I.C.O (*indirectness* di **C.**)

- P. Pazienti con mHSPC ad alto volume/rischio
- I. AAP/Doce + ADT
- C. ADT
- O. OS, PFS, QoL, Tollerabilità

Evidenze direttamente trasferibili nel caso la sola ADT rappresenti l'alternativa terapeutica standard

- P. Pazienti con mHSPC ad alto volume/rischio
- I. AAP + ADT
- **C.** Doce + ADT
- O. OS, PFS, QoL, Tollerabilità



Which outcome measures are most important?

The third key component of a well-formulated question is the delineation of particular outcomes that are of interest.

- Outcomes considered to be meaningful, and therefore addressed in a review, will not necessarily have been reported in individual studies.
- Including all important outcomes in a review will highlight gaps in the primary research and encourage researchers to address these gaps in future studies.

Which outcome measures are most important?

It is critical that outcomes used to assess adverse effects as well as outcomes used to assess beneficial effects are among those addressed by a review



Choosing outcomes

Desirable outcomes

- lower mortality
- reduced hospital stay
- reduced duration of disease
- reduced resource expenditure

Undesirable outcomes

- adverse reactions
- the development of resistance
- costs of treatment



Which outcome measures are most important?

The third key component of a well-formulated question is the delineation of particular outcomes that are of interest.

- Outcomes considered to be meaningful, and therefore addressed in a review, will not necessarily have been reported in individual studies.
- Including all important outcomes in a review will highlight gaps in the primary research and encourage researchers to address these gaps in future studies.



Outcomes

Should be

Journal of Clinical Epidemiology 64 (2011) 395-400

GRADE guidelines: 2. Framing the question and deciding on important outcomes

Gordon H. Guyatt^{a,*}, Andrew D. Oxman^b, Regina Kunz^c, David Atkins^d, Jan Brozek^a, Gunn Vist^b, Philip Alderson^e, Paul Glasziou^f, Yngve Falck-Ytter^g, Holger J. Schünemann^a

If evidence is lacking for an important outcome, this should be acknowledged, rather than ignoring the outcome - that uncertainty may have a bearing on the ultimate recommendation.

importance driven NOT evidence driven

Screening for prostate cancer (Review)

Ilic D, Neuberger MM, Djulbegovic M, Dahm P *Cochrane Database of Systematic Reviews* 2013, Issue 1.

Primary outcomes

Primary outcome measures for this review were prostate cancerspecific and all-cause mortality.

Secondary outcomes

Secondary outcome measures included:

- incident prostate cancers by stage and grade at diagnosis;
- metastatic disease at follow-up;
- quality of life;
- harms of screening (including both adverse outcomes from false-positive or false-negative results and their impact upon resulting treatment procedures); and
 - costs associated with screening programs.





STUDI CLINICI: METODOLOGIA

> Coordinatore Dr.ssa Stefania Gori

Evento ECM MODULO 4

REVISIONI SISTEMATICHE E METANALISI

NEGRAR 5/6 Aprile 2019 Centro Formazione IRCCS Ospedale Sacro Cuore Don Calabria

Misure riassuntive di effetto per varie tipologie di variabili statistiche



What type of outcome do yo	ou want to create?						
Data Type:	Description:						
 Dichotomous Continuous O-E and Variance 	Enter observed minus expected and its variance (e.g. calculated from individual patient data). Optionally ente number of participants with events and total number of participants in experimental and control groups.						
Generic Inverse Variance							
Other Data							
	< Back Next > Finish						

● ○ ○ · · · · · · · · · · · · · · · · ·	utcome Wizard					
New Outcome Wizard		? 🗊				
Which analysis method do you want to	use?					
Statistical Method	Analysis Model					
O Peto	Fixed Effect					
• Mantel-Haenszel	O Random Effects					
O Inverse Variance						
Exp[(O-E) / Var]						
Effect Measure						
O Peto Odds Ratio	O Mean Difference					
🗿 Odds Ratio	O Std. Mean Difference					
O Risk Ratio	O Name of Effect Measure:					
O Risk Difference	Hazard Ratio	\$				
Cancel < Back	Next >	Finish				

VARIABILE DI RISPOSTA


- di tipo quantitativo
 - assume uno spettro continuo di valori e viene misurata in riferimento a una scala a intervalli costanti.
- di tipo qualitativo
 - esprime categorie di risposta del tipo successo / insuccesso (di un trattamento somministrato).
- del tipo "tempo a evento"
 - rappresenta il tempo trascorso fino al verificarsi (o meno) di un evento.

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

A Systematic Review and Meta-analysis

Eliano Pio Navarese, MD, PhD; Michalina Kołodziejczak, MD; Volker Schulze, MD; Paul A. Gurbel, MD; Udaya Tantry, PhD; Yingfeng Lin, MD; Maximilian Brockmeyer, MD; David E. Kandzari, MD; Julia M. Kubica, MD; Ralph B. D'Agostino Sr., PhD; Jacek Kubica, MD, PhD; Massimo Volpe, MD; Stefan Agewall, MD; Dean J. Kereiakes, MD; and Malte Kelm, MD

Ann Intern Med. 2015;163:40-51



Group	Number of	Point	SE	Variance	Lower	Upper	Z Value	P Value	Q Value	P Value	1 ²
Random-effects analysis	Studies	Estimate			Limit	Limit					
Overall	26	-31.492	7.580	57.455	-46.348	-16.635	-4.155	0.000	187.788	0.000	86.687


Serum lipids and lipoproteins in malaria a systematic review and meta-analysis

Benjamin J Visser^{1,2,4}, Rosanne W Wieten^{1,2}, Ingeborg M Nagel³ and Martin P Grobusch^{1,2,4*} *Malaria Journal* 2013, **12**:442

			-			-						
Study or Subgroup	Mean	SD	lotal	Mean	SD	Iotal	Weight	IV, Random, 95% CI	Year		dom, 95% (
Seshadri 1981	2.82	0.09	30	4.4	0.11	39	7.1%	-1.58 [-1.63, -1.53]	1981			
Djoumessi 1989	3.18	0.96	37	4.16	1.55	37	5.9%	-0.98 [-1.57, -0.39]	1989		-	
Cuisinier-Raynal 1990	4.8	1.04	67	5	0.89	51	6.6%	-0.20 [-0.55, 0.15]	1990	-	•†	
Agbedana 1990	2.56	0.7	15	3.54	0.77	11	5.9%	-0.98 [-1.56, -0.40]	1990		-	
Mohanty 1992	2.7	0.87	60	4.77	0.91	83	6.7%	-2.07 [-2.36, -1.78]	1992			
Selvam 1992	3.9	1.04	98	5.18	0.83	174	6.9%	-1.28 [-1.52, -1.04]	1992	-		
Sumitha 1996	5.46	0.5	20	6.09	0.68	20	6.6%	-0.63 [-1.00, -0.26]	1996		-	
Das 1996	2.23	0.62	100	3.47	0.59	50	6.9%	-1.24 [-1.44, -1.04]	1996	-		
Erel 1998	2.96	0.8	60	3.4	1.12	50	6.6%	-0.44 [-0.81, -0.07]	1998	_	-	
Njoku 2001	2.95	0.35	33	4.2	0.49	22	6.9%	-1.25 [-1.49, -1.01]	2001	-		
Faucher 2002	3.49	0.88	47	3.87	0.66	47	6.7%	-0.38 [-0.69, -0.07]	2002	_	-	
Parola 2004	0	0	0	0	0	0		Not estimable	2004			
Kim 2008	1.97	0.7	55	4.38	0.67	52	6.8%	-2.41 [-2.67, -2.15]	2008			
Ogbodo 2008	2.27	0.43	20	2.88	0.58	15	6.6%	-0.61 [-0.96, -0.26]	2008		-	
Al Omar 2010	1.93	1.59	200	3.6	0.99	200	6.8%	-1.67 [-1.93, -1.41]	2010			
Vlfonkeu 2010	2.57	0.14	139	3.08	0.21	45	7.1%	-0.51 [-0.58, -0.44]	2010	•		
Eteng 2010	4.28	1.16	17	2.95	0.71	20		Not estimable	2010			
Гotal (95% СІ)			981			896	100.0%	-1.09 [-1.44, -0.74]		•		
Heterogeneity: Tau ² = 0	.44; Chi²	= 897.	72, df =	= 14 (P <	0.0000	1); I ² =	98%			-4 -2	0	2
Test for overall effect: Z	= 6.14 (F	o < 0.0	0001)							Cholesterol lower	•	ے erol higher

The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis

Khrisha B. Alphonsus^{a,*}, Yingying Su^a, Carl D'Arcy^{a,b} Complementary Therapies in Medicine 43 (2019) 188–195



VARIABILE DI RISPOSTA

- di tipo quantitativo
 - assume uno spettro continuo di valori e viene misurata in riferimento a una scala a intervalli costanti.
- di tipo qualitativo
 - esprime categorie di risposta del tipo successo / insuccesso (di un trattamento somministrato).
- del tipo "tempo a evento"
 - rappresenta il tempo trascorso fino al verificarsi (o meno) di un evento.

Risks, Rates and Odds

- **Risk** (proportion of persons with disease = *cumulative incidence*)
 - Risk Ratio = ratio of 2 cumulative incidence estimates = Relative Risk
- *Rate* (based on events per person-time = *incidence rate*)
 Rate Ratio = ratio of 2 incidence rates = *Relative Rate*
- **Odds** (the number of events divided by the number of non events)
 - Odds Ratio = ratio of 2 odds

INCIDENZA CUMULATIVA (IC)

Probabilità (rischio) di sviluppare la malattia in uno specifico periodo di tempo t

- assume follow-up completo
- è una proporzione perciò può assumere valori da 0 ad 1
- deve riferirsi ad uno specifico periodo di tempo

```
N° di persone che ammalano
tra il t<sub>0</sub> e t<sub>1</sub>
IC = \frac{1}{N^{\circ}} di persone non malate
all'inizio del periodo t<sub>0</sub>
```

Es. 5 si ammalano / 10 inizialmente non malati = 0.5

Risks, Rates and Odds

- **Risk** (proportion of persons with disease = *cumulative incidence*)
 - **Risk Ratio** = ratio of 2 cumulative incidence estimates = Relative Risk
- *Rate* (based on events per person-time = *incidence rate*)
 Rate Ratio = ratio of 2 incidence rates = *Relative Rate*
- **Odds** (the number of events divided by the number of non events)
 - Odds Ratio = ratio of 2 odds



Screening for prostate cancer (Review)

Ilic D, Neuberger MM, Djulbegovic M, Dahm P

Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD004720.


Figure 2. Forest plot of comparison: I Screening versus control, outcome: 1.3 Prostate cancer-specific mortality (subgroup analysis age)

Screening		Cont	rol		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl		
1.1.1 Men aged ≥ 45 years									
Quebec Subtotal (95% Cl)	153	31133 31133	75	15353 15353	18.7% 18.7 %	1.01 [0.76, 1.33] 1.01 [0.76, 1.33]			
Total events	153		75						
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.04 (F	P = 0.97)							
1.1.2 Men aged ≥ 50	years								
ERSPC	364	82816	522	99183	33.9%	0.84 [0.73, 0.95]	-		
Norrkoping	30	1494	130	7532	11.6%	1.16 [0.79, 1.72]			
Subtotal (95% CI)		84310		106715	45.5%	0.93 [0.69, 1.27]	•		
Total events	394		652						
Heterogeneity: Tau ² =				: 0.12); I ² :	= 59%				
Test for overall effect:	Z = 0.43 (i	P = 0.66)							
1.1.3 Men aged ≥ 55	years								
PLCO	98	38340	85	38345	17.5%	1.15 [0.86, 1.54]	+		
Stockholm	53	2374	506	24772	18.3%	1.09 [0.83, 1.45]			
Subtotal (95% CI)		40714		63117	35.9%	1.12 [0.92, 1.37]	•		
Total events	151		591						
Heterogeneity: Tau ² =				: 0.79); I ² :	= 0%				
Test for overall effect:	Z = 1.12 (i	P = 0.26)							
Total events	698		1318						
Heterogeneity: Tau ² =		r = 7.40 o		0 1 2) [.] I ² :	= 46%				
Test for overall effect:				0.12/,1	10 %		0.01 0.1 1 10 100		
Test for subgroup diff	,			(P = 0.59)	. I ² = 0%		Favours screening Favours control		

Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials

Paul L. Nguyen, MD	Jim C. Hu, MD, MPH	
Youjin Je, MS	Arti Parekh, BA	
Fabio A. B. Schutz, MD	Joshua A. Beckman, MD, MSc	
Karen E. Hoffman, MD, MPH, MHSc	Toni K. Choueiri, MD	JAMA. 2011;306(21):2359-2366

Relative Risk of All-Cause Mortality Associated With ADT Among Patients With Prostate Cancer



Risks, Rates and Odds

- **Risk** (proportion of persons with disease = *cumulative incidence*)
 - *Risk Ratio* = ratio of 2 cumulative incidence estimates = Relative Risk
- *Rate* (based on events per person-time = *incidence rate*)
 - Rate Ratio = ratio of 2 incidence rates = Relative Rate
- **Odds** (the number of events divided by the number of non events)
 - Odds Ratio = ratio of 2 odds

Incidence Rate

Incidence rate or person-time rate:

- is a measure of incidence that incorporates time directly into the denominator;
- describes how quickly disease occurs in a population

Number of new cases of disease or injury during specified period


Time each person was observed, totaled for all persons

Risks, Rates and Odds

- **Risk** (proportion of persons with disease = *cumulative incidence*)
 - *Risk Ratio* = ratio of 2 cumulative incidence estimates = Relative Risk
- *Rate* (based on events per person-time = *incidence rate*)
 - **Rate Ratio** = ratio of 2 incidence rates = *Relative Rate*
- **Odds** (the number of events divided by the number of non events)
 - Odds Ratio = ratio of 2 odds

Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: A systematic review and metaanalysis

Rebecca S. Holmes MD | Elizabeth Crabtree PhD | Marian S. McDonagh PharmD Diabetes Obes Metab. 2019;21:984–992.



Nocturnal hypoglycaemia event rates in adult patients with type 2 diabetes treated with daily degludec compared with glargine

Risks, Rates and Odds

- **Risk** (proportion of persons with disease = *cumulative incidence*)
 - *Risk Ratio* = ratio of 2 cumulative incidence estimates = Relative Risk
- Rate (based on events per person-time = incidence rate)
 - Rate Ratio = ratio of 2 incidence rates = Relative Rate
- **Odds** (the number of events divided by the number of non events)
 - Odds Ratio = ratio of 2 odds

Risks, Rates and Odds

• **Risk** (proportion of persons with disease = *cumulative incidence*)

Odds Ratios are used to compare the occurrence of the outcome of interest (e.g. disease or unfavourable event), given exposure to the variable of interest (e.g. health characteristic, or intervention). Most commonly used in case-control studies

• *Gaas* (the events)

evenus aiviaea by the number of non

es =

– Odds Ratio = ratio of 2 odds

Accepted Manuscript



TTE ARE OF

Single abnormal value on 3 hour oral glucose tolerance test during pregnancy is associated with adverse maternal and neonatal outcomes: A systematic review and meta-analysis

Jared T. Roeckner, MD, Luis Sanchez-Ramos, MD, Rubymel Jijon-Knupp, MD, Andrew M. Kaunitz, MD

Neonatal Hypoglycemia

Study	year	
GTT-0 Biri Corrado Kim Wang Bhat Subtotal (I	2009 2009 2002 2009 2005 -squared = 0.0%, p = 0.443)	2.94 (0.78, 11.11) 1.45 (0.66, 3.16) - 9.60 (0.86, 106.73) 1.56 (0.35, 7.05) (Excluded) 1.89 (1.04, 3.44)
Normal Glucose Screen		
Biri Chico Forest Kokanali Langer Langer Vambergue Wang Subtotal (I	2009 2005 1994 2014 1989 1987 2000 2009 -squared = 29.9%, p = 0.189)	$\begin{array}{c} 8.67 & (2.61, 28.79) \\ 0.48 & (0.07, 3.46) \\ 1.34 & (0.48, 3.71) \\ 1.46 & (0.13, 16.41) \\ 2.51 & (0.90, 7.02) \\ 3.33 & (0.63, 17.57) \\ 1.51 & (0.74, 3.08) \\ 1.66 & (0.94, 2.93) \\ 1.96 & (1.25, 3.08) \end{array}$
Gestational diabetes		
	2009 2005 1994 1987 2009 -squared = 50.0%, p = 0.092) ights are from random effects analysis	0.91 (0.26, 3.20) 0.30 (0.04, 2.26) 0.22 (0.08, 0.64) 2.17 (0.50, 9.31) 0.36 (0.20, 0.68) 0.50 (0.24, 1.05)
.1 .5 1 5 10 25		


Int. J. Cancer: **107,** 1023–1029 (2003) © 2003 Wiley-Liss, Inc.



THE ASSOCIATION BETWEEN STRESSFUL LIFE EVENTS AND BREAST CANCER RISK: A META-ANALYSIS

Saskia F.A. DUIJTS^{1*}, Maurice P.A. ZEEGERS¹ and Bart Vd BORNE²


Stressful Life Events



VARIABILE DI RISPOSTA

- di tipo quantitativo
 - assume uno spettro continuo di valori e viene misurata in riferimento a una scala a intervalli costanti.
- di tipo qualitativo
 - esprime categorie di risposta del tipo successo / insuccesso (di un trattamento somministrato).
- del tipo "tempo a evento"
 - rappresenta il tempo trascorso fino al verificarsi (o meno) di un evento.


Indicatori riassuntivi di effetto di variabili tempo-a-evento




• Hazard Ratio (KM+Cox)

Proportional Hazard Assumption

If we are comparing a new treatment with the standard treatment, it is assumed that the ratio of the hazard for an individual on a new treatment to that for an individual on the standard treatment remains constant over time



Treatment comparison and study



Treatment comparison and study

